
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is expected to continue leading the market with its strong management, innovative technology, and promising results in the use of CGM systems, especially in conjunction with other treatments for type 2 diabetes. Its commitment to addressing major health concerns and expanding into new markets while maintaining a positive financial outlook makes it a solid choice for investment. Despite potential competition and risks in the diabetes device sector, DexCom's track record and potential for growth make it an attractive investment opportunity.
Bears say
DexCom is facing potential risks in the T1 segment as well as potential challenges in expanding into the T2 market, with potential barriers including significant investments and competition from other non-insulin glucose lowering agents. Additionally, potential delays in market expansion and slower adoption of the 15-day sensors could hinder revenue growth and impact the company's margins. The current valuation multiple of 4.7x EV/Sales appears to be too low for a company with expected low-teens/20%+ revenue and EPS growth in 2026-2027, especially if one takes into account potential execution discounts. Management expects a 1H26 NIT RCT readout, but the current growth trend in the US has been decelerating, presenting further challenges to the company's growth prospects.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares